Intracoronary Administration of Drugs in Clinical Practice

S. V. Salo, Valentyn O. Shumakov, A. Y. Gavrylyshyn, O. Levchyshyna, S. S. Shpak
{"title":"Intracoronary Administration of Drugs in Clinical Practice","authors":"S. V. Salo, Valentyn O. Shumakov, A. Y. Gavrylyshyn, O. Levchyshyna, S. S. Shpak","doi":"10.30702/ujcvs/22.30(04)/ss051-1219","DOIUrl":null,"url":null,"abstract":"Intracoronary administration of drugs allows to achieve the fastest possible effect in interventional cardiology. This allows to avoid all the biological filters of the body and achieve the required concentration of the active substance at the injection site. Also, given the local action, systemic side effects are nearly absent. \nThe aim. To study the literature data of the leading countries of the world in the field of intracoronary drug administration. To analyze the experience of different centers on the use of various medications in the treatment of the phenomenon of distal microembolization. \nResults. One of the first drugs administered intracoronary was streptokinase for the treatment of acute myocardial infarction. After that, it became clear that this method of delivering drugs is possible and can be used. With the beginning of the treatment of acute coronary syndromes by stenting, one of the possible complications arose in the form of no-reflow. At the same time, realizing that this is a local problem, they began to use the possibility of intracoronary administration of drugs to treat this phenomenon. The main advantage of this method is quick response to drug administration. Today, the drugs of choice in the treatment of no-reflow are verapamil, adenosine, nitroprusside, adrenaline. On the other hand, probably the most common drug that is administered intracoronary is nitroglycerin. It is used as a vasodilator in the event of spasm of the coronary arteries. Subsequently, it has been recommended to deliver drugs via a microcatheter or aspiration catheter to achieve even more selective effect in the area of the affected vessel, and this also minimizes drug loss due to coronary reflux into the aortic sinuses while usinga guiding catheter. Work is also underway on the use of intracoronary insulin in acute coronary syndrome in order to reduce the area of damage in myocardial infarction. It is also very promising to study the introduction of stem cells directlyinto the myocardium through a microcatheter in order to regenerate the myocardium after a heart attack. \nConclusions. Intracoronary administration of drugs allows to achieve the maximum effect in the shortest possible time. Today, many drugs can be used in this way, starting from the treatment of the phenomenon of distal microembolization and ending with myocardial regeneration after myocardial infarction.","PeriodicalId":33680,"journal":{"name":"Ukrayins''kii zhurnal sertsevosudinnoyi khirurgiyi","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ukrayins''kii zhurnal sertsevosudinnoyi khirurgiyi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30702/ujcvs/22.30(04)/ss051-1219","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Intracoronary administration of drugs allows to achieve the fastest possible effect in interventional cardiology. This allows to avoid all the biological filters of the body and achieve the required concentration of the active substance at the injection site. Also, given the local action, systemic side effects are nearly absent. The aim. To study the literature data of the leading countries of the world in the field of intracoronary drug administration. To analyze the experience of different centers on the use of various medications in the treatment of the phenomenon of distal microembolization. Results. One of the first drugs administered intracoronary was streptokinase for the treatment of acute myocardial infarction. After that, it became clear that this method of delivering drugs is possible and can be used. With the beginning of the treatment of acute coronary syndromes by stenting, one of the possible complications arose in the form of no-reflow. At the same time, realizing that this is a local problem, they began to use the possibility of intracoronary administration of drugs to treat this phenomenon. The main advantage of this method is quick response to drug administration. Today, the drugs of choice in the treatment of no-reflow are verapamil, adenosine, nitroprusside, adrenaline. On the other hand, probably the most common drug that is administered intracoronary is nitroglycerin. It is used as a vasodilator in the event of spasm of the coronary arteries. Subsequently, it has been recommended to deliver drugs via a microcatheter or aspiration catheter to achieve even more selective effect in the area of the affected vessel, and this also minimizes drug loss due to coronary reflux into the aortic sinuses while usinga guiding catheter. Work is also underway on the use of intracoronary insulin in acute coronary syndrome in order to reduce the area of damage in myocardial infarction. It is also very promising to study the introduction of stem cells directlyinto the myocardium through a microcatheter in order to regenerate the myocardium after a heart attack. Conclusions. Intracoronary administration of drugs allows to achieve the maximum effect in the shortest possible time. Today, many drugs can be used in this way, starting from the treatment of the phenomenon of distal microembolization and ending with myocardial regeneration after myocardial infarction.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
临床应用中的冠状动脉内给药
冠状动脉内给药可以在介入心脏病学中实现最快的效果。这允许避开身体的所有生物过滤器,并在注射部位达到所需的活性物质浓度。此外,考虑到局部作用,系统性副作用几乎不存在。目标。研究世界领先国家在冠状动脉内药物管理领域的文献资料。分析不同中心使用各种药物治疗远端微栓塞现象的经验。后果最早在冠状动脉内给药的药物之一是链激酶,用于治疗急性心肌梗死。在那之后,很明显,这种递送药物的方法是可能的,并且可以使用。随着支架治疗急性冠状动脉综合征的开始,一种可能的并发症以无复流的形式出现。同时,意识到这是一个局部问题,他们开始利用冠状动脉内给药的可能性来治疗这种现象。这种方法的主要优点是对药物给药反应迅速。如今,治疗无复流的首选药物是维拉帕米、腺苷、硝普钠和肾上腺素。另一方面,冠状动脉内给药最常见的药物可能是硝酸甘油。在冠状动脉痉挛的情况下,它被用作血管舒张剂。随后,建议通过微导管或抽吸导管输送药物,以在受影响血管区域实现更具选择性的效果,这也最大限度地减少了在使用引导导管时因冠状动脉回流进入主动脉窦而造成的药物损失。在急性冠状动脉综合征中使用冠状动脉内胰岛素以减少心肌梗死的损伤面积的工作也在进行中。研究通过微导管将干细胞直接引入心肌以在心脏病发作后再生心肌也是非常有希望的。结论。冠状动脉内给药可以在尽可能短的时间内达到最大效果。如今,许多药物都可以这样使用,从治疗远端微栓塞现象开始,到心肌梗死后的心肌再生结束。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
42
审稿时长
6 weeks
期刊最新文献
Analysis of the Use of Non-Invasive Lung Ventilation Support in Newborns and Young Children after Cardiac Surgery Features of the Course of Atrial Fibrillation in Patients with the History of COVID-19: Impact on the Possibility and Tactics of Restoring Sinus Rhythm Features of Catheter Treatment of Non-Isthmus-Dependent Atrial Flutter Issues of Organization of the Cardiac Surgical Care in Ukraine under Martial Law Hemostasiological Aspects of PCI: Periprocedural Changes in the Activity of the Platelet Link of Hemocoagulation on the Background of Prior Double Antiplatelet Therapy in Patients with Chronic Coronary Syndrome
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1